RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus

EMA explains GMP and GDP flexibilities amid COVID-19

28 May 2020 | By Michael Mezher 

The European Medicines Agency (EMA) and its counterparts at the European Commission and Heads of Medicines Agencies have updated the...

Regulatory Exchange